Gelmetix 3rd in prestigious EIT Health Catapult competition

We’re delighted to announce that  on 3rd December, with total prize winnings of €210,000 available among the best performers. The seven finalists represented best-in-class innovations in biotech across Europe, having been selected from hundreds of entrants.

EIT Health Catapult is a unique competition and training programme that showcases biotech, medtech and digital health start-ups to leading experts and investors across Europe. The programme recognises and awards the very best business concepts, fast-tracking start-ups to become part of the EIT Health Community of world-leading companies. EIT Health is supported by the European Institute of Innovation & Technology (EIT), a body of the European Union.

This fantastic achievement is a huge accolade affirming Gelmetix’s DXM product as a game-changer in disc nucleus augmentation and revolutionising treatment for chronic back pain.